Department Rheumatolgy, Mongi Slim hospital, La marsa, Tunisia.
Expert Rev Clin Immunol. 2024 Dec;20(12):1437-1448. doi: 10.1080/1744666X.2024.2388693. Epub 2024 Aug 11.
Behçet disease (BD) is an inflammatory multisystem disorder of unknown etiology, believed to be triggered by infection and environmental factors in genetically predisposed individuals. The significance of understanding BD lies in its impact on global health due to its diverse clinical manifestations and geographical distribution.
This review discusses the epidemiology of BD, emphasizing its prevalence estimated at 10.3 (95% CI, 6.1, 17.7) per 100,000 population, with higher rates observed in regions historically linked to the Silk Route. The criteria for diagnosis are explored, focusing on clinical manifestations that guide healthcare professionals in identifying and managing BD. Additionally, the review encompasses treatment strategies, highlighting TNF-alpha inhibitors as pivotal biologics and newer agents like IL-1 inhibitors and Ustekinumab that broaden the therapeutic options for BD.
Our work provides insights into the evolving landscape of treatments for BD, emphasizing the expanding role of newer agents alongside established therapies like TNF-alpha inhibitors.
贝切特病（BD）是一种病因不明的炎症性多系统疾病，被认为是由遗传易感性个体中的感染和环境因素引发的。了解 BD 的意义在于其对全球健康的影响，因为它具有多种临床表现和地理分布。
本综述讨论了 BD 的流行病学，强调其患病率估计为每 10 万人中有 10.3（95%置信区间，6.1，17.7），在历史上与丝绸之路相关的地区观察到更高的发病率。探讨了诊断标准，重点关注指导医疗保健专业人员识别和管理 BD 的临床表现。此外，该综述还包括治疗策略，强调 TNF-α 抑制剂作为关键的生物制剂，以及 IL-1 抑制剂和乌司奴单抗等新型药物拓宽了 BD 的治疗选择。
我们的工作深入了解了 BD 治疗方法的不断发展，强调了新型药物在 TNF-α 抑制剂等既定疗法之外的扩展作用。
